Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Elzbieta Kaszuba, Lund University
ClinicalTrials.gov Identifier:
NCT01801722
First received: February 25, 2013
Last updated: February 28, 2013
Last verified: February 2013
  Purpose

The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.


Condition
Chronic Obstructive Pulmonary Disease
Chronic Heart Failure

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.

Resource links provided by NLM:


Further study details as provided by Lund University:

Primary Outcome Measures:
  • Percentage of patients with elevated NT-proBNP. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.


Secondary Outcome Measures:
  • Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Echocardiography was performed once in each referred patient. Three months was a period of data collection.


Enrollment: 75
Study Start Date: April 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
NT-proBNP,ejection fraction ,COPD stage.
The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.

Detailed Description:

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.

  1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
  2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
  3. Electrocardiography.
  4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
  5. Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.
  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients aged 65 years and older with a registered diagnosis of COPD.

Criteria

Inclusion Criteria:

  • Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion Criteria:

  • Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
  • psychiatric disorders or terminal illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01801722

Locations
Sweden
Primary health care center.
Olofström, Blekinge, Sweden, 29332
Sponsors and Collaborators
Lund University
Investigators
Principal Investigator: Elzbieta Kaszuba, PhD student Lund University
  More Information

No publications provided

Responsible Party: Elzbieta Kaszuba, PhD student, Lund University
ClinicalTrials.gov Identifier: NCT01801722     History of Changes
Other Study ID Numbers: 502008, DN50/2008
Study First Received: February 25, 2013
Last Updated: February 28, 2013
Health Authority: Sweden: Regional Ethical Review Board

Additional relevant MeSH terms:
Heart Failure
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Heart Diseases
Cardiovascular Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 20, 2014